Patent application number | Description | Published |
20080292679 | BIODEGRADABLE DRUG DELIVERY SYSTEM - A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics. | 11-27-2008 |
20090004245 | Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens - A drug delivery device includes a contact lens along with a drug delivery zone disposed above an applied axis of the lens. A colored layer is disposed over the drug delivery zone in order to mark a color of the drug delivery zone. | 01-01-2009 |
20090081277 | PHARMACEUTICAL FORMULATIONS AND METHODS FOR TREATING OCULAR CONDITIONS - Biodegradable drug delivery systems suitable for injection into an ocular region or site and methods for treating ocular conditions. The drug delivery systems provide increased drug residency time and attendant therapeutic benefit. | 03-26-2009 |
20090082796 | MODIFIED TENOTOMY SCISSORS WITH CONJUNCTIVA RISERS - A tenotomy scissors for implantation procedures generally includes a first blade having a handle and a tip with a cutting edge thereon, a second blade having a handle and a tip with a cutting edge thereon, along with a swivel pivotally attaching the first and second blades for enabling insertion of the cutting edges for cutting a pocket in tissue when the handle is operated. One or more risers upstanding from at least one of the blade tips are provided for keeping the pocket open to facilitate insertion of an implant device. | 03-26-2009 |
20090143348 | POLYSACCHARIDE GEL COMPOSITIONS AND METHODS FOR SUSTAINED DELIVERY OF DRUGS - Methods of producing a biocompatible polysaccharide gel composition having sustained release properties are disclosed. Also disclosed is a biocompatible polysaccharide gel composition having sustained release properties, a method of treating a disease or condition using the present biocompatible polysaccharide gel composition, and a method of controlling rate of release of at least one target solute from the biocompatible polysaccharide gel composition. Pharmaceutical compositions which include the present biocompatible polysaccharide gel composition also are disclosed. | 06-04-2009 |
20090148527 | INTRAOCULAR FORMULATION - Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition. The formulation can also be used to treat non-ocular conditions such as articular pathologies. | 06-11-2009 |
20090155314 | Dermal filler - Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin. | 06-18-2009 |
20090196905 | STABILIZATION OF MITOCHONDRIAL MEMBRANES IN OCULAR DISEASES AND CONDITIONS - Methods of treating ocular diseases and conditions using biodegradable ocular implants containing cyclosporine to inhibit mitochondrial permeability transition pore formation are disclosed. | 08-06-2009 |
20100015158 | METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION - Compositions and methods for treating dry age related macular degeneration (dry AMD) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA). | 01-21-2010 |
20100074957 | INTRAOCULAR FORMULATION - Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition. The formulation can also be used to treat non-ocular conditions such as articular pathologies. | 03-25-2010 |
20100098772 | DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING NEOVASCULARIZATION - Anti-angiogenesis compositions, and methods of using such compositions, useful for intraocular to treat neovascularization. The compositions can have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps. | 04-22-2010 |
20100104654 | PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF - Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma. | 04-29-2010 |
20100124565 | BIODEGRADABLE ALPHA-2 AGONIST POLYMERIC IMPLANTS AND THERAPEUTIC USES THEREOF - Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure. | 05-20-2010 |
20100247606 | INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING OCULAR CONDITIONS - Biocompatible, bioerodible sustained release implants and microspheres for intracameral or anterior vitreal placement include an anti-hypertensive agent and a biodegradable polymer effective to treat an ocular hypertensive condition (such as glaucoma) by relapsing therapeutic amount of the anti-hypertensive agent over a period of time between | 09-30-2010 |
20100278898 | INTRAOCULAR PRESSURE REDUCTION WITH INTRACAMERAL BIMATOPROST IMPLANTS - The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the prostamide from the implant to provide an amount of the prostamide effective to prevent or reduce a symptom of an ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm's Canal. | 11-04-2010 |
20110182966 | INTRACAMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS - Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye. | 07-28-2011 |
20120141532 | Botulinum Toxin Formulation - Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects. | 06-07-2012 |
20120245505 | INTRACAMERAL DEVICES FOR SUSTAINED DELIVERY - Described herein are intracameral drug and/or therapeutic bioactive agent delivery devices comprising a substantially cylindrical structure for at least partial placement into the anterior chamber of an eye The intracameral delivery devices have a sustained release material associated with at least a portion of the device and at least one drug and/or therapeutic bioactive agent associated with said sustained release material. | 09-27-2012 |
20120263779 | BIODEGRADABLE DRUG DELIVERY SYSTEM - A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics. | 10-18-2012 |
20130017243 | SUSTAINED-RELEASE RESERVOIR IMPLANTS FOR INTRACAMERAL DRUG DELIVERY - The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days. | 01-17-2013 |
20130017268 | PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF - Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma. | 01-17-2013 |
20130040895 | Pharmaceutical Formulations and Methods for Treating Ocular Conditions - Biodegradable drug delivery systems suitable for injection into an ocular region or site and methods for treating ocular conditions. The drug delivery systems provide increased drug residency time and attendant therapeutic benefit. | 02-14-2013 |
20130071349 | BIODEGRADABLE POLYMERS FOR LOWERING INTRAOCULAR PRESSURE - The present invention provides a method of treating glaucoma, the method comprising the step of placing a polymer in an eye of a patient, which biologically degrades over a period of time to release biodegradants, which are effective to lower the intraocular pressure of the patient, thereby treating glaucoma. Said polymer is preferably selected from the group consisting of polymers of lactic acid, glycolic acid and/or mixtures thereof. More preferably the polymer is a copolymer of lactic acid and glycolic acid, e.g. a copolymer comprising from 50 to 100% lactic acid and from 0 to 50% glycolic acid, by weight. | 03-21-2013 |
20130172353 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS - This invention is directed to a compound of Formula I | 07-04-2013 |
20130225505 | MUTEINS OF HUMAN TEAR LIPCALIN FOR TREATING NEOVASCULAR DISEASE OF THE ANTERIOR SEGMENT OF THE HUMAN EYE - Disclosed herein is a method of treating neovascular diseases of the anterior segment of the human eye, the method comprising administering to the eye muteins of human tear lipocalin that target VEGF. | 08-29-2013 |
20140045945 | INTRACAMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS - Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye. | 02-13-2014 |
20140086974 | BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR THE SUSTAINED RELEASE OF PROTEINS - Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye. | 03-27-2014 |
20140271780 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT - Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described. | 09-18-2014 |
20140302007 | BOTULINUM TOXIN FORMULATION - neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the | 10-09-2014 |
20140314868 | PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF - Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma. | 10-23-2014 |
20140322206 | METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION - Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA). | 10-30-2014 |
20140341966 | STEROID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS - Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent. | 11-20-2014 |
20140341968 | Intraocular Drug Delivery Systems - Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer. | 11-20-2014 |
20140356438 | PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS - Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time. | 12-04-2014 |
20150080845 | POLYMER SYSTEM FOR SECURING IMPLANTS IN SYRINGE NEEDLES - Disclosed herein are methods of delivering implants to a target organ with an implant administration device, where the implant administration device includes a polymer retainer. Methods of making polymer retainers and methods of securing an implant within an implant administration device using a polymer retainer are also disclosed herein. | 03-19-2015 |